Press Brief

5:14
Ibrutinib/rituximab is superior to FCR for younger CLL patients in the frontline setting
Tait Shanafelt
6:19
MAIA trial: addition of daratumumab to Rd in newly diagnosed transplant-ineligible MM
Thierry Facon
5:26
Specific BCL2 mutation confers resistance to venetoclax in progressive CLL
Piers Blombery
6:21
Ibrutinib emerging as the new standard of care for frontline elderly CLL: ALLIANCE results
Jennifer Woyach
5:45
CD19 CAR T-cells plus ibrutinib in R/R CLL may improve response & decrease CRS
Jordan Gauthier
5:30
Long-term follow-up after SCRI-CAR19v1 in R/R ALL patients who proceeded to transplant
Corinne Summers
6:20
Updated pivotal ELIANA study results for CAR T-cell product tisagenlecleucel in ALL
Stephan Grupp
7:30
Genetic targeting in sickle cell disease
Erica Esrick
6:40
PAUSE: perioperative management of AF patients receiving direct oral anticoagulants
James Douketis
1:11
Update on ELIANA for CAR T-cell product tisagenlecleucel in ALL
Stephan Grupp
4:40
Reduced R-CHOP in favourable-prognosis DLBCL doesn’t compromise outlook
Viola Poeschel
2:52
Reducing chemotherapy in DLBCL: FLYER results
Viola Poeschel
7:19
Checkpoint inhibitors augument CD19 CAR T-cell therapy in relapsed B-ALL
Shannon Maude
6:32
Luspatercept reduces transfusion burden in MDS-related anemia: MEDALIST results
Alan List
7:37
Opioid use in sickle cell is not associated with in-hospital mortality in the US
Oladimeji Akinola Akinboro
5:57
REACH: hydroxyurea for sickle cell anemia in sub-saharan Africa
Leon Tshilolo
The content of VJHemOnc is intended for healthcare professionals